Table 5.

Diagnosis efficiency of combined diagnostic approaches.

Diagnosis specificity and sensitivity
ARMS-qPCR with cytology
	Bethesda V/VI or (with) BRAF mutation	Bethesda II to IV with WT BRAF
Malignant	48	7	sensitiviry with 95% CI: 0.873 (0.749-0.943)
Benign	2	12	specificity with 95% CI: 0.857 (0.562-0.975)
ARMS-qPCR and NGS with cytology
	Bethesda V/VI or (with) pathogenic mutation	Bethesda II to IV without pathogenic mutation
Malignant	52	3	sensitiviry with 95% CI: 0.945 (0.839-0.986)
Benign	3	11	specificity with 95% CI: 0.785 (0.488-0.943

Sensitivity and specificity of diagnosis based on combination of cytology and ARMS-qPCR for BRAF V600E mutation detection (Bethesda V/VI with/or BRAF mutation are considered malignant) and combination of cytology, ARMS-qPCR and NGS (Bethesda V/VI and/or pathogenic mutation are considered malignant).